Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.

King MT, Nguyen PL, Boldbaatar N, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV, Orio PF 3rd.

Cancer. 2018 Sep 1;124(17):3528-3535. doi: 10.1002/cncr.31568. Epub 2018 Jul 5.

PMID:
29975404
2.

Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer.

Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV.

JAMA Oncol. 2015 Jun;1(3):334-40. doi: 10.1001/jamaoncol.2014.284.

PMID:
26181182
3.

Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.

Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):147-52. doi: 10.1016/j.ijrobp.2009.04.085. Epub 2009 Sep 8.

PMID:
19744800
4.

Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.

Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):904-911. doi: 10.1016/j.ijrobp.2017.07.034. Epub 2017 Jul 31.

PMID:
29063853
5.

Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy.

King MT, Nguyen PL, Boldbaatar N, Yang DD, Muralidhar V, Tempany CM, Cormack RA, Hurwitz MD, Suh WW, Pomerantz MM, D'Amico AV, Orio PF 3rd.

Brachytherapy. 2019 Jan 9. pii: S1538-4721(18)30680-9. doi: 10.1016/j.brachy.2018.12.001. [Epub ahead of print]

PMID:
30638910
6.

Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts.

Merrick GS, Butler WM, Galbreath RW, Fiano R, Adamovich E.

J Contemp Brachytherapy. 2015 Dec;7(6):430-6. doi: 10.5114/jcb.2015.56763. Epub 2015 Dec 30.

7.

Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.

Keane FK, Chen MH, Zhang D, Moran BJ, Braccioforte MH, D'Amico AV.

Cancer. 2015 Aug 15;121(16):2713-9. doi: 10.1002/cncr.29420. Epub 2015 Apr 29.

8.

Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy.

Nguyen PL, Chen MH, Zhang Y, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV.

J Urol. 2012 Oct;188(4):1151-6. doi: 10.1016/j.juro.2012.06.010. Epub 2012 Aug 15.

9.

Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.

Rosenberg JE, Chen MH, Nguyen PL, Braccioforte MH, Moran BJ, D'Amico AV.

Clin Genitourin Cancer. 2012 Mar;10(1):21-5. doi: 10.1016/j.clgc.2011.10.003. Epub 2011 Nov 29.

PMID:
22130293
10.

Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer.

Muralidhar V, Xiang M, Orio PF 3rd, Martin NE, Beard CJ, Feng FY, Hoffman KE, Nguyen PL.

J Contemp Brachytherapy. 2016 Feb;8(1):1-6. doi: 10.5114/jcb.2016.58080. Epub 2016 Feb 29.

11.

Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA.

Merrick GS, Galbreath RW, Butler WM, Fiano R, Adamovich E.

J Contemp Brachytherapy. 2017 Aug;9(4):297-303. doi: 10.5114/jcb.2017.69588. Epub 2017 Aug 30.

12.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

13.

Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study.

Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW.

Cancer. 2007 Oct 1;110(7):1485-92.

14.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

15.

Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).

Russo AL, Chen MH, Aizer AA, Hattangadi JA, D'Amico AV.

BJU Int. 2012 Oct;110(7):973-9. doi: 10.1111/j.1464-410X.2012.11470.x.

16.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
17.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

18.

Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.

Kittel JA, Reddy CA, Smith KL, Stephans KL, Tendulkar RD, Ulchaker J, Angermeier K, Campbell S, Stephenson A, Klein EA, Wilkinson DA, Ciezki JP.

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):884-93. doi: 10.1016/j.ijrobp.2015.02.047. Epub 2015 May 8.

PMID:
25962627
19.

Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.

Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, Beard CJ, Feng FY, Hoffman KE, Choueiri TK, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):828-35. doi: 10.1016/j.ijrobp.2015.07.2281. Epub 2015 Jul 29.

20.

Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.

Arvold ND, Chen MH, Moul JW, Moran BJ, Dosoretz DE, Bañez LL, Katin MJ, Braccioforte MH, D'Amico AV.

J Urol. 2011 Jul;186(1):91-6. doi: 10.1016/j.juro.2011.03.003. Epub 2011 May 14.

PMID:
21571341

Supplemental Content

Support Center